RxDB
ICD-9-CM Codes ICD-9-PCS Codes

0018 - Infusion of immunosuppressive antibody therapy

Overview

GEM Conversion to ICD-10 PCS

Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach
Fs: 10000 – Introduction of Immunosuppressive into Peripheral Vein, Open
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach
Fs: 10000 – Introduction of Immunosuppressive into Peripheral Vein, Percutaneous
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach
Fs: 10000 – Introduction of Immunosuppressive into Central Vein, Open
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach
Fs: 10000 – Introduction of Immunosuppressive into Central Vein, Percutaneous
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach
Fs: 10000 – Introduction of Immunosuppressive into Peripheral Artery, Open
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach
Fs: 10000 – Introduction of Immunosuppressive into Peripheral Artery, Percutaneous
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
Fs: 10000 – Introduction of Immunosuppressive into Central Artery, Open
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
Fs: 10000 – Introduction of Immunosuppressive into Central Artery, Percutaneous
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach
Fs: 10000 – Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening

Sibling Codes

Implantation of chemotherapeutic agent
Infusion of drotrecogin alfa (activated)
Administration of inhaled nitric oxide
Injection or infusion of nesiritide
Injection or infusion of oxazolidinone class of antibiotics
High-dose infusion interleukin-2 [IL-2]
Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance
Infusion of vasopressor agent
Infusion of immunosuppressive antibody therapy
Disruption of blood brain barrier via infusion [BBBD]